Investment in Axol Bioscience Ltd

RNS Number : 2234U
Intuitive Investments Group plc
01 April 2021
 

1 April 2021

Intuitive Investments Group plc

Investment in Axol Bioscience Ltd

Intuitive Investments Group plc (AIM: IIG), ("IIG" or the "Company"), a closed-end investment company focussed on the life sciences sector, announces an investment of £250,000 in Axol Bioscience Ltd ("Axol") (the "Investment").  Axol has reversed into Censo Biotechnologies Ltd ("Censo") by way of share for share exchange (the "Enlarged Group"). The Investment is part of a £3.6 million funding round to provide working capital for the Enlarged Group. IIG will hold 2.625% of the Enlarged Group's A ordinary shares, which have a participating preference ahead of the Enlarged Group 's ordinary shares. On a fully diluted basis IIG will have an interest in 0.964% of the voting rights of the Enlarged Group.

Axol produces high quality human cell products, particularly in relation to pluripotent stem cell (hiPSC) and critical reagents such as media and growth supplements, which are sold to medical research and drug discovery organisations . Axol also provides contract research for example customising cell lines for customers, such as reprogramming and differentiation. Censo is a specialist contract research organisation with products, complementary to those produced by Axol, in complex cell biology, specialising in human neurodegenerative, neuroinflammatory and inflammatory disease models. The Chairman of Axol is Jonathan Milner, who is the company's co-founder and was previously deputy chairman of Abcam plc.

Axol, per the company's unaudited management accounts, achieved a loss after tax for the year ended 31 December 2020 of £399,718 on sales of £2,526,187 and, as at 31 December 2020, had net assets of £1,093,393.

For further information, please contact:

Intuitive Investments Group plc

www.iigplc.com

David Evans, Executive Chairman

Robert Naylor, CEO

Via Walbrook PR

 

 

Strand Hanson Limited - Nominated Adviser

+44 (0) 20 7409 3494

James Harris / James Dance / James Bellman

 

 

 





Turner Pope Investments (TPI) Ltd - Broker

+44 (0) 20 3657 0050

Andrew Thacker / Zoe Alexander

 

 

 

Walbrook PR Limited - Media & Investor Relations

+44 (0)20 7933 8780 or intuitive@walbrookpr.com

Sam Allen / Paul McManus

+44 (0)7502 558 258 / +44 (0) 7980 541 893

About Intuitive Investments Group plc

The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSDLEFFEFSEDD
UK 100

Latest directors dealings